Post-Hemorrhagic Anemia Treatment Market size was over USD 5.61 billion in 2024 and is anticipated to cross USD 11.82 billion by 2037, witnessing more than 5.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of post-hemorrhagic anemia treatment is estimated at USD 6.15 billion.
The growth of the market can be attributed to the higher cases of road accidents and trauma. Sudden accidents can cause severe injuries that leads to heavy blood loss. Around the world, 1.35 million people die due to road accident every year. Nearly 3,700 people per day die worldwide in collisions involving automobiles, buses, motorbikes, bicycles, lorries, or pedestrians.
In addition to these, factors that are believed to fuel the market growth of post-hemorrhagic anemia treatment include the growing number of trauma cases across the globe, and increasing prevalence of bleeding disorders, such as hemophilia and Von Willebrand disease. In 2020, approximately 210,000 people in the world suffered from hemophilia, and about 84,000 were diagnosed with Von Willebrand disease. Along with these, rise in awareness levels regarding anemia, and escalating technological developments in the pharmaceutical sector, especially in developed and developing nations. Furthermore, surge in the percentage of population with a family history of anemia and blood diseases is projected to elevate the total number of cases of acute post-hemorrhagic anemia. This in turn is predicted to offer abundant growth opportunities to the market in the near future.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
USD 5.61 billion |
|
Base Year Market Size (2024) |
USD 11.82 billion |
|
Forecast Year Market Size (2037) |
USD 11.82 billion |
|
Regional Scope |
|
The global post-hemorrhagic anemia treatment market is also segmented and analyzed for demand and supply by treatment into blood transfusion, surgery, iron supplements, extra oxygen, fluids, and others, out of which, the blood transfusion segment is anticipated to hold the largest share in the global post-hemorrhagic anemia treatment market. As a patient suffering from this type anemia quickly loses a large amount of blood, performing a blood transfusion becomes a necessity. Rising need for blood transfusion and rise in the collection of donated bloods is assessed to be a major factor to boost the growth of the market segment in the future. Globally, 118.5 million units of donated blood are collected year, but more would need to be collected to supply all the people who require transfusions. Furthermore, the patient suffering with sickle cell anemia, needs blood transfusion in every 4-6 weeks for a long period.
The global post-hemorrhagic anemia treatment market is segmented and analyzed for demand and supply by end user into hospitals, clinics, ambulatory surgical centers, and others. Out of all, the hospitals segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the high preference of patients to get treatment from a medical professional in a hospital facility. Apart from this, increase in number of patient admissions in hospitals is also forecasted to bolster the segment growth in the years to come.
Our in-depth analysis of the global post-hemorrhagic anemia treatment market includes the following segments:
|
By Treatment |
|
|
By End User |
|
North America Market Forecast
North America industry is poised to dominate majority revenue share of 36% by 2037, The growth of the market in the region can be attributed majorly to the high number of hospital admissions, and the rising government focus to improve healthcare infrastructure in the region. Moreover, the market growth in North America is also credited to the rising number of people suffering from sickle cell anemia. In many severe cases, post-hemorrhagic anemia treatment is continued along the specific sickle cell disease drugs. Approximately 100,000 Americans are afflicted by sickle cell diseases. In addition to this, about 1 in every 365 Black or African-American babies is affected by SCD. Furthermore, the region’s market growth is attributed to high healthcare spending, and availability of well-established medical facilities in the region. According to the Centers for Medicare and Medicaid Services, U.S. health care spending reached USD 3.8 trillion or USD 11,582 per person in 2019. As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent that year. In addition, strong footprint of major market players is also predicted to propel the market growth in the region in the coming years.
Asia-Pacific Market Forecast
The Asia-Pacific post-hemorrhagic anemia treatment market, amongst the market in all the other regions, is projected to hold the notable market share by the end of 2037. The growth of the market in the region can be majorly credited to rising cases of traffic accident and growing count of heart patient. As per the annual report from Ministry of Road Transport & Highways on road accidents in India 2021, there were 412,432 instances of road accidents in 2021, which resulted in 153,972 fatalities and 384,448 severe injuries. Furthermore, in Japan, the overall number of heart-related deaths reached about 206 thousand cases in 2020.
Pfizer Inc. announced the acquisition of Global Blood Therapeutics, Inc., a leading developer and provider of treatments for SCD patients. With this acquisition, Pfizer aims to advance these treatments in the rare hematology space of sickle cell diseases.
F. Hoffmann-La-Roche Ltd. Announced the approval of the European Commission for the expansion of Hemlibra. With this expansion, Roche aims to include bleeding episodes in hemophilia A patients without the use of factor VII inhibitors
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?